| BIOGEN INC. DL -,0005 | 226.600 / +2.95% |
| Date/Time | 01/25 / 20:44 |
| Chg. / Chg.(%) | 6.500 / +2.95% |
| Bid | - |
| Ask | - |
| Open | 221.450 |
| Previous Close | 220.100 |
| High | 226.600 |
| Low | 221.450 |
| Volume [EUR] | 0.000 |
| Volume [Units] | 0 |
| Price fixings | 2 |
| ISIN | US09062X1037 |
| Security | IDP |
| Exchange | Stuttgart |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| NASDAQ | 275.5400 |  |
806,822 |
| IEX | 275.29 | |
45,463 |
| Cboe US | 275.44 | |
34,580 |
| London Inter.. | 273.36 | |
2,334 |
| TradeGate | 226.000 | |
983 |
| Xetra | 226.60 | |
774 |
| Vienna Globa.. | 226.60 | |
114 |
| gettex | 226.300 | |
54 |
| Frankfurt | 225.5000 | |
20 |
| München | 221.50 |  |
0 |
| Hamburg | 220.65 | |
0 |
| Düsseldorf | 226.35 | |
0 |
| Berlin | 226.70 | |
0 |
| Hannover | 220.65 | |
0 |
| Stuttgart | 226.600 | |
0 |
| Lang & Schwa.. | 223.900 | |
|
| Mexico | 5,375.00 | |
129 |
News
- Biogen to Launch Pioneering Study to Develop Digital Biomarkers of Cognitive Health Using Apple Watch and iPhone
01/11/2021 / 13:30 - GlobeNewswire - Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma® (onasemnogene abeparvovec)
01/08/2021 / 13:30 - GlobeNewswire - The European Commission Grants Marketing Authorization for PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Relapsing-Remitting Multiple Sclerosis
12/21/2020 / 13:30 - GlobeNewswire - Biogen agrees to $22M settlement to resolve claims on illegal business
12/17/2020 / 20:04 - TeleTrader - Biogen Files New Drug Application for Aducanumab in Japan
12/10/2020 / 04:30 - GlobeNewswire
Real-time